BIZARRE: Lrmr - You Need To See This

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injections of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich’s ataxia (FA).

Benzinga · Sep 29, 2025

Larimar Stock Plunges As FDA Asks For Additional Data To Resolve Clinical Hold On Friedreich's Ataxia Program

Larimar Therapeutics Inc (NASDAQ: LRMR) has rec

Benzinga · Feb 15, 2022